News - Page 64 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Establishing the Psychedelic Research Center Consortium

Establishing the Psychedelic Research Center Consortium

Post published:February 10, 2023
Post category:2022 Year in Review

Read more about the article Key Psychedelic Research Themes in 2022

Key Psychedelic Research Themes in 2022

Post published:February 9, 2023
Post category:2022 Year in Review

Read more about the article Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Post published:February 8, 2023
Post category:Press Release

Read more about the article Bullseye Chart: The Psychedelic Drug Development Pipeline

Bullseye Chart: The Psychedelic Drug Development Pipeline

Post published:February 8, 2023
Post category:2022 Year in Review

Read more about the article Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Post published:February 8, 2023
Post category:Press Release

Read more about the article Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First Step, Potential International Catalyst

Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First Step, Potential International Catalyst

Post published:February 8, 2023
Post category:Opinions

Read more about the article Panel: Neuroimaging in Psychedelic Research

Panel: Neuroimaging in Psychedelic Research

Post published:February 7, 2023
Post category:2022 Year in Review

Read more about the article Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Post published:February 7, 2023
Post category:Press Release

Read more about the article PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

Post published:February 7, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Post published:February 6, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.